短期联合干扰素雾化吸入治疗呼吸道合胞病毒性喘息性支气管炎的临床疗效

Aerosol inhalation of terbutaline and budesonide and interferon in short-term for respiratory syncytial viral asthmatic bronchitis

目的探析短期联合干扰素雾化吸入治疗呼吸道合胞病毒性喘息性支气管炎的临床疗效。方法选择本院2011年4月至2015年4月所收治107例呼吸道合胞病毒性喘息性支气管炎患者作为研究对象，分为观察组（n=54）与对照组（n=53）。对照组应用特布他林、布地奈德进行雾化吸入治疗，2次／天，疗程1周；观察组在对照组基础上联合干扰素α1b进行雾化吸入，比较两组喘息、咳嗽与肺部哕音等症状消失时间与住院时间、治疗有效率及不良反应发生率。结果观察组喘息、咳嗽、肺部哕音等临床症状消失时间均短于对照组，住院时间也更短，差异有统计学意义（P〈0．05）。观察组治疗有效率为83．3％（45／54），高于对照组62．3％（33／53），差异有统计学意义俨〈0．05）。观察组、对照组不良反应发生率分别为3．7％（2／54）、1．9％（1／53），差异无统计学意义（P〉0．05）。结论短期联合干扰素雾化吸入治疗呼吸道合胞病毒性喘息性支气管炎可快速缓解患者临床症状，疗效佳，且不良反应少，值得推广应用。

Objective To explore the clinical curative effect of the aerosol inhalation of terbutaline and budesonide and interferon in short-term for respiratory syncytial viral asthmatic bronchitis. Methods 107 patients with respiratory syncytial viral asthmatic bronchitis treated at our hospital from April, 2011 to April, 2015 were selected as study objects and were divided into an observation group （n=54） and a control group （n=53）. The control group was treated with the aerosol inhalation of terbutaline and budesonide and the observation group with the aerosol inhalation of terbutaline and budesonide and interferon ctlb, twice one day for 1 week. The times for the disappearing of wheezing, cough, pulmonary tales, and other symptoms, hospitalization time, the efficacy, and the incidence of adverse reactions were compared between these two groups. Results The times for the disappearing of wheezing, cough, pulmonary rales, and other symptoms and the hospitalization time were shorter in the observation group than in the control group （P 〈 0.05）. The efficacy was higher in the observation group than in the control group [83.3% （45/54） vs. 62.3% （33/53）, P〈0.05]. The incidence of adverse reactions was 3.7% （2/54）in the observation group and 1.9% （1/53） in control group, with no statistical difference （P〉 0.05）. Conclusions The aerosol inhalation of terbutaline and budesonide and interferon in shortterm for respiratory syncytial viral asthmatic bronchitis can quickly relieve the patients＇ clinical symptoms, is curatively effective, and has few adverse reactions. It is worth being generalized.